Genmab — Juni 2025

[Solsen]

Lidt om samarbejdet med Lundbec https://www.researchgate.net/publication/392007308_Rational_selection_of_the_monoclonal_a-synuclein_antibody_amlenetug_Lu_AF82422_for_the_treatment_of_a-synucleinopathies/fulltext/683034fb6b5a287c3043f3cb/Rational-selection-of-the-monoclonal-a-synuclein-antibody-amlenetug-Lu-AF82422-for-the-treatment-of-a-synucleinopathies.pdf?origin=publication_detail&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHVibGljYXRpb25Eb3dubG9hZCIsInByZXZpb3VzUGFnZSI6InB1Y

[Solsen]

..Lundbeck. Ved ikke om jeg rigtigt tror på stoffet

[ProinvestorNEWS]

Knock-Your-Socks-Off-News – June 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-june-2025-genmab-p3wze/

[E_L]

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma https://www.sciencedirect.com/science/article/pii/S2473952925003143

[Raun]

Biontech BNT116 -
https://x.com/EvanKirstel/status/1932149953184375160

[Solsen]

Det bliver spændende at følge @Raun

[E_L]

the Ph3 Acasunlimab trial adding a lot of new recruitment centers https://clinicaltrials.gov/study/NCT06635824?tab=history&a=8&b=9&compareMode=sideBySide#version-content-panel

[w]

AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength. Hæver fra 2566 til 2661kr

[w]

Human Verification

(finimize.com)

[Solsen]

Plus 100 new sites And boost targets. Are we back on trac ?

[E_L]

In full swing... let's see if they can replicate the speed with which they executed on Epcoritamab... that went very fast (is going very fast i should say), but this they have to do alone...

[E_L]

ASCO 2025 presentations via https://www.genmabmedicalaffairs.com/congress?filv1=17

[Solsen]

Looks like Rina-S also are running fast

[Solsen]

I have been a little cautious on Acasunlimab after Biontech left. But there is a chance that Biontech where wrong.

[E_L]

the fact that they started a Melanoma trial with Acasunlimab is a strong signal i would think

[Solsen]

Yes I agree.

[lahn1]

De 2 nye endpoint kan vel være andet end positive, selvom jeg primært ser dem som det. Lyder plasma kontrol lidt som vi var inden på ved resultaterne af ph2, at en individuel doserings regime (timing) ift Aca koncentrationen i plasma ser ud til at kunne optimere effekten ? Discontinuation rate er vel kun forberedelse på godkendelse vs Docetaxel i 2 L og måske bedre forståelse for AE ift med mulige fremtidige kombinationer. Hvordan læse I andre de nye end points ?

[Solsen]

Acasunlimab has a huge potential. Tahi seems very bullish. But data on limited pts until now. But if they can show high number and long responses in NSCLC in second line it could be big.

[lahn1]

Sorry, jeg fik vist blandet koncentratione af acasunlimab i plasma sammen med t-cell exhaustion.

[E_L]

only Time to Treatment Discontinuation Due to AE is new. (the other was already there, the old 5. ) to me the question is more; why wasn't that there in the first place (logical measure)